QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$67.14
-0.31 (-0.46%)
(As of 02/6/2023 04:31 PM ET)
Add
Compare
Today's Range
$65.14
$67.90
50-Day Range
$41.19
$70.77
52-Week Range
$29.27
$84.31
Volume
1.69 million shs
Average Volume
3.09 million shs
Market Capitalization
$11.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.57

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
9.0% Downside
$61.57 Price Target
Short Interest
Bearish
7.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
1.04mentions of Exact Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$60,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.67) to ($2.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

796th out of 1,027 stocks

Medical Laboratories Industry

19th out of 25 stocks

EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

Cathie Woods' Ark Innovation ETF Set To Rebound in 2023? (EXAS)
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023?
Exact Sciences Corp Stock Price Is Trending Up Here's Why
Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Exact Sciences Corp Stock Price Is Trending Up Here's Why (EXAS)
Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.
1 Soaring Growth Stock to Buy and Hold for 10 Years
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
Cathie Wood: Ark Continues Exact Sciences Dump
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
Cathie Wood Is Crushing It This Year Thanks To 9 Stocks
3 Top Stocks Already up More Than 20% In 2023
Is Exact Sciences a Buy?
SVB Securities Keeps Their Buy Rating on Exact Sciences (EXAS)
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
11/01/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$61.57
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
-8.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

Net Income
$-595,630,000.00
Pretax Margin
-36.28%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$19.66 per share

Miscellaneous

Free Float
175,374,000
Market Cap
$11.93 billion
Optionable
Optionable
Beta
1.42

Social Links


Key Executives

  • Kevin T. ConroyKevin T. Conroy
    Chairman, President & Chief Executive Officer
  • Jeffrey Thomas ElliottJeffrey Thomas Elliott
    Executive VP, Chief Operating & Financial Officer
  • Sandra Statz
    Senior VP-Clinical & Regulatory Affairs
  • Gary Frings
    Chief Information Officer
  • Scott C. Johnson
    Senior Vice President-Assay Research & Development













EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2023?

12 Wall Street analysts have issued 12-month price targets for Exact Sciences' shares. Their EXAS share price forecasts range from $35.00 to $85.00. On average, they predict the company's stock price to reach $61.57 in the next twelve months. This suggests that the stock has a possible downside of 8.7%.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2023?

Exact Sciences' stock was trading at $49.51 at the beginning of 2023. Since then, EXAS stock has increased by 36.2% and is now trading at $67.45.
View the best growth stocks for 2023 here
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our EXAS earnings forecast
.

How can I listen to Exact Sciences' earnings call?

Exact Sciences will be holding an earnings conference call on Tuesday, February 21st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 647-362-9199 with passcode "4437608".

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Monday, November, 1st. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.08. The medical research company had revenue of $456.38 million for the quarter, compared to analysts' expectations of $429.04 million. Exact Sciences had a negative trailing twelve-month return on equity of 22.10% and a negative net margin of 35.73%. During the same quarter last year, the firm posted ($0.36) EPS.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $550.70 million-$552.70 million, compared to the consensus revenue estimate of $506.48 million.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.03%), Sumitomo Mitsui Trust Holdings Inc. (3.02%), Baillie Gifford & Co. (2.78%), C WorldWide Group Holding A S (0.35%), Peregrine Capital Management LLC (0.34%) and New York State Common Retirement Fund (0.29%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $67.45.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $11.98 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.10) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 2/6/2023 by MarketBeat.com Staff